ArticleRegenerative therapy2025
Novel preparation of laponite based theranostic silver nanocomposite for drug delivery, radical scavenging and healing efficiency for wound care management after surgery.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Dissolving Silver Nanoparticles Modulate the Endothelial Monocyte-Activating Polypeptide II (EMAP II) by Partially Unfolding the Protein Leading to tRNA Binding Enhancement.International journal of molecular sciences · 2026Article
- LaponitePharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, laponite (LAP) was used to develop the silver (Ag) based nanocomposite for improved anti-bacterial action and wound healing properties. The amphiphilic co-polymers such as PLGA polymer was embedded with the surface of LAP molecules and polyethyleneimine (PEI) through the interaction of hydrophobic binding and it was formed as LAP/PLA-PEG/PEI formulation through the coupling chemistry. The Ag nanoparticles was loaded into formulation to develop LAP/PLA-PEG/PEI/Ag nanocomposite and characterized by different analytical techniques. The UV-Vis and XRD results report that the nanocomposite has shown Surface Plasmon Resonance (SPR) peak at 415 nm for AgNPs particles and provide the strong intensity peak along with 48 nm particle size, respectively. The HR-TEM image showed that the LAP/PLA-PEG/PEI/Ag nanocomposite has shown crystal lattice with spherical morphology. In addition, the synthesized nanocomposite requested in the swelling along with degradation, radial scavenging activity and drug releasing behaviour by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.